We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

147 hedge funds and large institutions have $292M invested in ImmunityBio in 2023 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 57 increasing their positions, 28 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

247% more capital invested

Capital invested by funds: $84.1M → $292M (+$208M)

183% more call options, than puts

Call options by funds: $14.5M | Put options by funds: $5.13M

131% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 13

104% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 28

12% more funds holding

Funds holding: 131 → 147 (+16)

1.24% more ownership

Funds ownership: 7.47% → 8.71% (+1.2%)

Holders
147
Holders Change
+16
Holders Change %
+12.21%
% of All Funds
2.14%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
30
Increased
57
Reduced
28
Closed
13
Calls
$14.5M
Puts
$5.13M
Net Calls
+$9.38M
Net Calls Change
+$9.57M

Top Buyers

1
State Street
State Street
Massachusetts
+$21.2M
2
Goldman Sachs
Goldman Sachs
New York
+$2.67M
3
Jane Street
Jane Street
New York
+$2.58M
4
Morgan Stanley
Morgan Stanley
New York
+$2.52M
5
Rafferty Asset Management
Rafferty Asset Management
New York
+$2.32M

Top Sellers

1
AC
Armistice Capital
New York
-$5.87M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$4.23M
3
Group One Trading
Group One Trading
Illinois
-$1.4M
4
National Bank of Canada
National Bank of Canada
Quebec, Canada
-$1.07M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$852K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$66.9M -$4.23M -1,347,162 -9%
BlackRock
2
BlackRock
New York
$53.8M -$316K -100,852 -0.9%
State Street
3
State Street
Massachusetts
$47.5M +$21.2M +6,751,317 +248%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$17M +$1.8M +573,281 +20%
CS
5
Credit Suisse
Switzerland
$7.68M -$13.3K -4,229 -0.3%
JP Morgan Chase
6
JP Morgan Chase
New York
$7.14M -$82.3K -26,220 -2%
Northern Trust
7
Northern Trust
Illinois
$6.81M +$641K +204,302 +18%
Goldman Sachs
8
Goldman Sachs
New York
$6.42M +$2.67M +850,874 +199%
Morgan Stanley
9
Morgan Stanley
New York
$6.02M +$2.52M +801,535 +201%
Charles Schwab
10
Charles Schwab
California
$5.74M +$292K +92,991 +9%
Bank of America
11
Bank of America
North Carolina
$4.48M +$2.21M +702,978 +372%
Jane Street
12
Jane Street
New York
$4.12M +$2.58M +821,643 New
Rafferty Asset Management
13
Rafferty Asset Management
New York
$3.71M +$2.32M +739,808 New
AH
14
Allen Holding
New York
$3.45M – – –
Invesco
15
Invesco
Georgia
$3.22M +$1.87M +595,890 +1,310%
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$2.97M +$1.85M +591,101 New
PI
17
Putnam Investments
Massachusetts
$2.68M +$1.68M +534,201 New
N
18
Nuveen
North Carolina
$2.62M +$142K +45,198 +9%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$2.42M -$112K -35,792 -7%
Barclays
20
Barclays
United Kingdom
$2.41M +$1.37M +435,172 +981%
CCA
21
Clearwater Capital Advisors
Illinois
$2.23M +$153K +48,700 +12%
HP
22
Harbourvest Partners
Massachusetts
$1.69M – – –
Citigroup
23
Citigroup
New York
$1.57M +$960K +305,990 +5,073%
AllianceBernstein
24
AllianceBernstein
Tennessee
$1.43M -$32.7K -10,430 -4%
Swiss National Bank
25
Swiss National Bank
Switzerland
$1.32M -$67.5K -21,500 -8%
1
2 3 4 5

IBRX Hedge Fund Activity: Q4 2023 in Review

147 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2023, worth a combined $292M — up 247% from $84.1M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new IBRX positions and 13 closed out — a net gain of 17 holders — while 57 added to existing stakes and 28 trimmed.

The largest buyer was State Street, adding an estimated $21.2M. The largest seller was Armistice Capital, exiting entirely with an estimated $5.87M sold.

  • 147 institutional investors held ImmunityBio (IBRX) as of Q4 2023, up from 131 in Q3 2023.
  • Funds reported $292M of ImmunityBio stock for Q4 2023, up 247% quarter-over-quarter.
  • 30 funds opened new ImmunityBio positions in Q4 2023 and 13 closed out, a net change of +17 holders.
  • The largest ImmunityBio buyer in Q4 2023 was State Street, an estimated $21.2M added.
  • The largest ImmunityBio seller in Q4 2023 was Armistice Capital, an estimated $5.87M sold.

Based on aggregated 13F filings for Q4 2023.